Claims
- 1. A pharmaceutical composition comprising effective amounts of an angiotensin II receptor antagonist and an ACAT inhibitor as active ingredients.
- 2. A pharmaceutical composition according to claim 1 wherein the angiotensin II receptor antagonist is irbesartan, valsartan, candesartan, or telmisartan.
- 3. A pharmaceutical composition according to claim 1 wherein the angiotensin II receptor antagonist is losartan.
- 4. A pharmaceutical composition according to claim 1 wherein the angiotensin II receptor antagonist is olmesartan.
- 5. A pharmaceutical composition according to claim 1 wherein the ACAT inhibitor is FR-129169, CI-1011, F-1394, F-12511, T-2591, FCE-28654, K-10085, HL-004, NTE-122, FR-186054, N-(1-pentyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropaneamide or a pharmacologically acceptable salt thereof.
- 6. A pharmaceutical composition according to claim 1 wherein the ACAT inhibitor is N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropaneamide or a pharmacologically acceptable salt thereof.
- 7. A pharmaceutical composition according to claim 1 wherein the angiotensin II receptor antagonist is olmesartan and the ACAT inhibitor is N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropaneamide.
- 8. A pharmaceutical composition according to claim 1 wherein the angiotensin II receptor antagonist is losartan and the ACAT inhibitor is N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropaneamide.
- 9. A pharmaceutical combination according to claim 8 wherein the angiotensin II receptor antagonist is losartan, irbesartan, valsartan, candesartan, olmesartan, or telmisartan and the ACAT inhibitor is FR-129169, CI-1011, F-1394, F-12511, T-2591, FCE-28654, K-10085, HL-004, NTE-122, FR-186054, N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropaneamide, or N-(1-pentyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropaneamide or a pharmacologically acceptable salt thereof.
- 10. A pharmaceutical composition according to claim 9 wherein the ACAT inhibitor is N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropaneamide or a pharmacologically acceptable salt thereof.
- 11. A pharmaceutical composition according to claim 9 wherein the angiotensin II receptor antagonist is losartan or olmesartan.
- 12. A method for the prevention or treatment of arteriosclerosis in a warm-blooded animal which comprises administering an angiotensin II receptor antagonist and an ACAT inhibitor to a warm-blooded animal suffering from or susceptible to arteriosclerosis.
- 13. A method according to claim 12 wherein the angiotensin II receptor antagonist is irbesartan, valsartan, candesartan, or telmisartan.
- 14. A method according to claim 12 wherein the angiotensin II receptor antagonist is losartan.
- 15. A method according to claim 12 wherein the angiotensin II receptor antagonist is olmesartan.
- 16. A method according to claim 12 wherein the ACAT inhibitor is FR-129169, CI-1011, F-1394, F-12511, T-2591, FCE-28654, K-10085, HL-004, NTE-122, FR-186054, or N-(1-pentyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropaneamide or a pharmacologically acceptable salt thereof.
- 17. A method according to claim 12 wherein the ACAT inhibitor is N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropaneamide or a pharmacologically acceptable salt thereof.
- 18. A method according to claim 12, wherein the angiotensin II receptor antagonist is losartan, irbesartan, valsartan, candesartan, olmesartan, or telmisartan and the ACAT inhibitor is FR-129169, CI-1011, F-1394, F-12511, T-2591, FCE-28654, K-10085, HL-004, NTE-122, FR-186054, N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropaneamide, or N-(1-pentyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropaneamide or a pharmacologically acceptable salt thereof.
- 19. A method for the prevention or treatment of ischemic heart disease in a warm-blooded animal which comprises administering an angiotensin II receptor antagonist and an ACAT inhibitor to a warm-blooded animal suffering from or susceptible to ischemic heart disease.
- 20. A method according to claim 19 wherein the angiotensin II receptor antagonist is irbesartan, valsartan, candesartan, or telmisartan.
- 21. A method according to claim 19 wherein the angiotensin II receptor antagonist is losartan.
- 22. A method according to claim 19 wherein the angiotensin II receptor antagonist is olmesartan.
- 23. A method according to claim 19 wherein the ACAT inhibitor is FR-129169, CI-1011, F-1394, F-12511, T-2591, FCE-28654, K-10085, HL-004, NTE-122, FR-186054, or N-(1-pentyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropaneamide or a pharmacologically acceptable salt thereof.
- 24. A method according to claim 19 wherein the ACAT inhibitor is N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropaneamide or a pharmacologically acceptable salt thereof.
- 25. A method according to claim 19, wherein the angiotensin II receptor antagonist is losartan, irbesartan, valsartan, candesartan, olmesartan, or telmisartan and wherein the ACAT inhibitor is FR-129169, CI-1011, F-1394, F-12511, T-2591, FCE-28654, K-10085, HL-004, NTE-122, FR-186054, N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropaneamide, or N-(1-pentyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropaneamide or a pharmacologically acceptable salt thereof.
Priority Claims (1)
Number |
Date |
Country |
Kind |
2001-257435 |
Aug 2001 |
JP |
|
Parent Case Info
[0001] This is a Continuation-in-Part application of International Application No. PCT/JP02/08629 filed Aug. 27, 2002 which is incorporated herein by reference in its entirety.
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
PCT/JP02/08629 |
Aug 2002 |
US |
Child |
10789340 |
Feb 2004 |
US |